Russell Investments Group
MRTX

Russell Investments Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Russell Investments Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-266
Closed -$15.6K – 3403
2023
Q4 		$15.6K Sell
266
-5,329
-95% -$300K ﹤0.01% 2775
2023
Q3 		$244K Sell
5,595
-53,002
-90% -$1.89M ﹤0.01% 2449
2023
Q2 		$2.12M Sell
58,597
-5,677
-9% -$234K ﹤0.01% 1527
2023
Q1 		$2.39M Buy
64,274
+4,248
+7% +$191K ﹤0.01% 1470
2022
Q4 		$2.72M Buy
60,026
+33,186
+124% +$2.15M 0.01% 1402
2022
Q3 		$1.87M Buy
26,840
+2,701
+11% +$200K ﹤0.01% 1585
2022
Q2 		$1.62M Sell
24,139
-34,115
-59% -$2.17M ﹤0.01% 1706
2022
Q1 		$4.79M Buy
58,254
+9,848
+20% +$1.01M 0.01% 1182
2021
Q4 		$7.1M Buy
48,406
+9,680
+25% +$1.5M 0.01% 1069
2021
Q3 		$6.85M Buy
38,726
+5,190
+15% +$835K 0.01% 1078
2021
Q2 		$5.42M Buy
33,536
+20,589
+159% +$3.31M 0.01% 1293
2021
Q1 		$2.22M Sell
12,947
-27,913
-68% -$5.53M ﹤0.01% 1823
2020
Q4 		$8.97M Buy
40,860
+5,746
+16% +$1.24M 0.02% 921
2020
Q3 		$5.83M Buy
35,114
+14,338
+69% +$1.96M 0.01% 1050
2020
Q2 		$2.37M Sell
20,776
-3,982
-16% -$386K 0.01% 1531
2020
Q1 		$1.91M Sell
24,758
-4,524
-15% -$406K ﹤0.01% 1492
2019
Q4 		$3.77M Buy
29,282
+6,937
+31% +$669K 0.01% 1376
2019
Q3 		$1.75M Sell
22,345
-185
-0.8% -$17.4K ﹤0.01% 1753
2019
Q2 		$2.32M Buy
22,530
+36
+0.2% +$2.8K ﹤0.01% 1596
2019
Q1 		$1.65M Buy
+22,494
New +$1.53M ﹤0.01% 1820
2017
Q2 		– Sell
-11,309
Closed -$59K – 3060
2017
Q1 		$59K Buy
+11,309
New +$62K ﹤0.01% 2879

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Russell Investments Group's MRTX Position: Q1 2024 in Review

Russell Investments Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 266 shares — an estimated $15.6K sold.

Russell Investments Group first reported a position in MRTX in Q1 2017 and held it in 21 quarters. The position peaked at $8.97M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Russell Investments Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Russell Investments Group sold 266 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $15.6K.
  • Russell Investments Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2017 and held it in 21 quarters.
  • Russell Investments Group's Mirati Therapeutics, Inc. Common Stock position peaked at $8.97M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Russell Investments Group's 13F filing for Q1 2024, filed 8 May 2024.